Lorence Kim Buys Shares of Revolution Medicines

Lorence Kim recently acquired 3,127 shares of Revolution Medicines, Inc. (NasdaqGS: RVMD) on June 18, 2026. The stock traded near $169.51 on Wednesday, reflecting ongoing interest in the biotechnology company's progress.

Insider Buying and Selling at Revolution Medicines, Inc.

Lorence Kim wasn't the only insider making moves at Revolution Medicines. On the same day, other insiders such as Flavia Borellini, Sushil Patel, Frank Clyburn, and Elizabeth Anderson also bought shares, with Clyburn purchasing an additional 1,191 shares. These transactions were not planned under Rule 10b5-1 plans.

Other Institutional Activity in Revolution Medicines

Institutional investors have also been active in Revolution Medicines. BlackRock, Inc. increased its stake by 2,286,050 shares, now holding 11,212,706 shares valued at approximately $1.09 billion, marking a 25.6% increase. On the other hand, Farallon Capital Management LLC reduced its holdings by 978,000 shares, now holding 13,604,796 shares worth about $1.32 billion, a 6.7% decrease. Janus Henderson Group PLC also decreased its position by 2,537,006 shares, leaving it with 9,766,496 shares valued at $949.5 million, a 20.6% reduction. Meanwhile, Vanguard Capital Management LLC opened a new position with 8,362,284 shares worth about $813.2 million.

Revolution Medicines, Inc. Stock Down 18.5%

Shares of Revolution Medicines traded near $169.51 on Wednesday. The company has a market cap of $35.3 billion and a forward P/E ratio of -29.07, reflecting its unprofitable status. The stock's 52-week range is between $34.00 and $166.84. It has a beta of 1.407, indicating higher volatility compared to the market. Revolution Medicines maintains a strong liquidity position with a current ratio of 6.795 and a quick ratio of 6.589.

Analysts Set New Price Targets

Analysts remain optimistic about Revolution Medicines' prospects. On June 10, 2026, Evercore ISI Group maintained a 'buy' rating with a price target of $220. RBC Capital also maintained a 'buy' rating with a target of $182 on June 2, 2026. Other firms like HC Wainwright & Co. and Oppenheimer reiterated 'buy' ratings with targets of $195 on June 1, 2026. The consensus recommendation is a strong buy, with a mean target price of $187.29 from 21 analysts.

About Revolution Medicines

Revolution Medicines, Inc., headquartered in Redwood City, California, is a clinical-stage biotechnology company focused on developing targeted therapies for cancers driven by RAS mutations. Led by CEO Dr. Mark A. Goldsmith, the company is working on RAS(ON) inhibitors and companion inhibitors to treat various solid tumors. With 883 employees, Revolution Medicines is advancing its pipeline through various clinical trials.

Bottom Line

Lorence Kim's recent share purchase highlights ongoing insider confidence in Revolution Medicines. Investors and analysts are closely watching the company's development of targeted cancer therapies. As a clinical-stage biotech firm, Revolution Medicines presents both opportunities and risks, with institutional investors actively adjusting their positions based on the company's progress.